The FDA’s latest reshuffle of its top drug and biologics leaders lands biotech in yet another plot twist—but this one may read more like a quirky chapter break than a full-blown cliffhanger for investors.
FDA’s New Cast at the Top
The Food…
Family offices didn’t just come back to the deal table in April – they showed up with term sheets in one hand and stethoscopes in the other.
Healthcare Becomes the New Family Office Heirloom
After a cautious March tied to geopolitical jitters…
In a market where capital efficiency has become the new currency of credibility, Eli Lilly & Co. (LLY) appears to be writing a decidedly modern playbook for growth—one acquisition at a time. The Indianapolis-based pharmaceutical heavyweight has quietly assembled a portfolio of…
Health care may not have the meme-stock glamour of AI chips, but this spring the sector is quietly reminding investors why 'boring' can be beautiful. A trio of updates from Incyte (INCY), Pfizer (PFE) and Eupraxia Pharmaceuticals (NASDA: EPRX) is painting a…
Nanobiotix’s (NBTX) latest preclinical data suggest that its Nanoprimer technology may do for lipid nanoparticle (LNP) DNA immunotherapy what noise-cancelling headphones did for air travel: make a powerful experience markedly more tolerable. For investors watching the crossroad of oncology and genetic medicines,…
Walmart’s (WMT) latest move into digital health reads less like a retail side-hustle and more like an opening bell in the next leg of the GLP‑1 trade, with syringes, smartphones, and stock tickers all lining up on aisle 7. As weight‑loss drugs…
In the ever-evolving world of oncology innovation, a bold question is being asked: “Can Targeted Alpha Therapy Cure Cancer?” That’s the headline theme of Tribe Public’s next CEO Presentation and Q&A Webinar, scheduled for Tuesday, April 14, 2026, at 8 a.m. PT / 11 a.m.…
Big Pharma spent the week shopping again, snapping up a fresh crop of biotech and pharmaceutical names in deals that underscore one message: pipelines are the new gold, and the majors are still happily paying spot prices. From autoimmune bets to allergy…
Yes indeed, Eupraxia Pharmaceutical's (NASDAQ: EPRX) EP-104 is quietly auditioning for a starring role in eosinophilic esophagitis—and for once, the gastroenterologist, the allergist, and the payer might actually clap at the same time.
A Chronic Disease Finally Meets a Long-Term Plan
Eosinophilic…
GeoVax’s (GOVX) latest update on its GEO-MVA program reads less like a small-cap press release and more like a biotech coming-of-age story, with Phase 3 now on the horizon and global health agencies finally circling the dance floor. For investors, the mpox/smallpox…